United States Biotechnology & Medical Research

Olema Pharmaceuticals Inc (OLMA)

Track

Olema Pharmaceuticals Inc. experienced recent insider trading activity characterized by net selling. Director Harmon Cyrus executed sales totaling approximately $291,163 over the past ninety days. These divestments occurred amidst a period where the stock price declined by 18.9%, following a recent earnings report that missed expectations.
Ticker: OLMA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Olema Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 24 Jul 2026
Value US$430,270.94 | Price 455.24 | Shares 95,671 (+21.6%)
Proposed sale 24 Jul 2026
Value US$1,063,816.59 | Price 282.21 | Shares 87,175
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-27 2026-07-24 S Sale
2.9
Harmon Cyrus
Non-Executive Director
95,671 +21.6%
455.24
US$430,271 		95,671 +21.6% 455.24 US$430,271
2026-07-24 2026-07-24 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
87,175
282.21
US$1,063,817 		87,175 282.21 US$1,063,817
2026-07-27 2026-07-23 S Sale
2.9
Harmon Cyrus
Non-Executive Director
26,230 +48.1%
299.88
US$1,569,813 		26,230 +48.1% 299.88 US$1,569,813
2026-07-23 2026-07-23 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
1,000
11.58
US$100,000 		1,000 11.58 US$100,000
2026-03-16 2026-03-16 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
4,166
16.61
US$69,178 		4,166 16.61 US$69,178
2026-03-16 2026-03-16 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
100,000
16.08
US$1,607,719 		100,000 16.08 US$1,607,719
2026-03-11 2026-03-11 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
50,000
15.94
US$796,796 		50,000 15.94 US$796,796
2026-03-10 2026-03-10 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
53,206
17.00
US$904,566 		53,206 17.00 US$904,566
2026-03-09 2026-03-09 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
241,999
13.45
US$3,254,933 		241,999 13.45 US$3,254,933
2026-03-05 2026-03-04 S Sale
3.6
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
233 -100.0%
24.69
US$5,753 		233 -100.0% 24.69 US$5,753
2026-03-05 2026-03-04 S Sale
3.6
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
24,767 -99.1%
24.25
US$600,600 		24,767 -99.1% 24.25 US$600,600
2026-03-04 2026-03-04 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
24.43
US$488,654 		20,000 24.43 US$488,654
2026-03-04 2026-03-04 PrS Proposed sale
3.6
Mitchell Shawnte

Officer

Officer
25,000
23.94
US$598,500 		25,000 23.94 US$598,500
2026-03-05 2026-03-03 S Sale
3.6
Mitchell Shawnte

CHIEF LEGAL OFFICER

Officer
15,000 -100.0%
23.01
US$345,150 		15,000 -100.0% 23.01 US$345,150
2026-03-03 2026-03-03 PrS Proposed sale
3.6
Mitchell Shawnte

Officer

Officer
15,000
23.01
US$345,153 		15,000 23.01 US$345,153
2026-02-27 2026-02-27 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
6,521
25.00
US$163,026 		6,521 25.00 US$163,026
2026-02-24 2026-02-24 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
25.00
US$500,002 		20,000 25.00 US$500,002
2026-02-23 2026-02-23 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
10,000
24.30
US$243,000 		10,000 24.30 US$243,000
2026-02-23 2026-02-23 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
20,000
24.00
US$480,007 		20,000 24.00 US$480,007
2026-02-12 2026-02-12 PrS Proposed sale
4.1
Kovacs Shane William Charles

Former Officer

Officer
10,000
23.85
US$238,498 		10,000 23.85 US$238,498
2026-01-21 2026-01-20 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.4%
26.88
US$268,800 		10,000 -1.4% 26.88 US$268,800
2026-01-20 2026-01-20 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
10,000
26.88
US$268,763 		10,000 26.88 US$268,763
2026-01-15 2026-01-15 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
100,000
28.73
US$2,873,215 		100,000 28.73 US$2,873,215
2026-01-15 2026-01-15 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
100,000 -41.7%
28.73
US$2,873,000 		100,000 -41.7% 28.73 US$2,873,000
2026-01-16 2026-01-14 S Sale
2.9
Harmon Cyrus
Non-Executive Director
3,489 -0.5%
29.12
US$101,600 		3,489 -0.5% 29.12 US$101,600
2026-01-14 2026-01-14 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
3,489
29.12
US$101,603 		3,489 29.12 US$101,603
2026-01-14 2026-01-14 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
50,000
28.87
US$1,443,631 		50,000 28.87 US$1,443,631
2026-01-14 2026-01-14 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
35,003 -6.1%
28.99
US$1,014,737 		35,003 -6.1% 28.99 US$1,014,737
2026-01-14 2026-01-14 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
14,997 -2.5%
28.60
US$428,914 		14,997 -2.5% 28.60 US$428,914
2026-01-15 2026-01-13 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
3,822 -1.6%
28.01
US$107,054 		3,822 -1.6% 28.01 US$107,054
2026-01-14 2026-01-13 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
200 -0.0%
28.49
US$5,698 		200 -0.0% 28.49 US$5,698
2026-01-14 2026-01-13 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
49,800 -8.4%
27.60
US$1,374,480 		49,800 -8.4% 27.60 US$1,374,480
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
3,822
28.01
US$107,069 		3,822 28.01 US$107,069
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
50,000
27.60
US$1,380,113 		50,000 27.60 US$1,380,113
2026-01-14 2026-01-12 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
10,000 -6.5%
28.34
US$283,400 		10,000 -6.5% 28.34 US$283,400
2026-01-12 2026-01-12 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
10,000
28.34
US$283,363 		10,000 28.34 US$283,363
2025-12-23 2025-12-23 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
99,509
27.66
US$2,752,165 		99,509 27.66 US$2,752,165
2025-12-23 2025-12-23 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
99,509 -95.7%
27.66
US$2,752,419 		99,509 -95.7% 27.66 US$2,752,419
2025-12-29 2025-12-22 S Sale
2.9
Harmon Cyrus
Non-Executive Director
2,881 -0.4%
28.53
US$82,195 		2,881 -0.4% 28.53 US$82,195
2025-12-23 2025-12-22 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
100,000 -64.9%
28.04
US$2,804,000 		100,000 -64.9% 28.04 US$2,804,000
2025-12-22 2025-12-22 PrS Proposed sale
2.9
Harmon Cyrus

Officer

Officer
2,881
28.53
US$82,182 		2,881 28.53 US$82,182
2025-12-22 2025-12-22 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
100,000
28.04
US$2,804,039 		100,000 28.04 US$2,804,039
2025-12-23 2025-12-19 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
6,046 -1.1%
31.39
US$189,784 		6,046 -1.1% 31.39 US$189,784
2025-12-23 2025-12-19 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
43,729 -7.3%
30.40
US$1,329,362 		43,729 -7.3% 30.40 US$1,329,362
2025-12-23 2025-12-19 PlS Planned sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
1,225 -0.2%
28.08
US$34,398 		1,225 -0.2% 28.08 US$34,398
2025-12-23 2025-12-19 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
12,921 -11.1%
28.93
US$373,805 		12,921 -11.1% 28.93 US$373,805
2025-12-23 2025-12-19 S Sale
4.0
Zojwalla Naseem

Chief Medical Officer

Officer
57,079 -32.8%
28.03
US$1,599,924 		57,079 -32.8% 28.03 US$1,599,924
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
41,840 -100.0%
30.48
US$1,275,283 		41,840 -100.0% 30.48 US$1,275,283
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
193,056 -82.2%
29.71
US$5,735,694 		193,056 -82.2% 29.71 US$5,735,694
2025-12-23 2025-12-19 S Sale
3.9
CLARK IAN T
Non-Executive Director
29,904 -11.3%
28.83
US$862,132 		29,904 -11.3% 28.83 US$862,132
2025-12-19 2025-12-19 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
51,000
30.46
US$1,553,447 		51,000 30.46 US$1,553,447
2025-12-19 2025-12-19 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
70,000
28.19
US$1,973,561 		70,000 28.19 US$1,973,561
2025-12-19 2025-12-19 PrS Proposed sale
3.9
CLARK IAN T

Director

Non-Executive Director
264,800
29.73
US$7,873,502 		264,800 29.73 US$7,873,502
2025-09-18 2025-09-18 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
13,086
8.33
US$108,978 		13,086 8.33 US$108,978
2025-09-18 2025-09-18 S Sale
2.9
Harmon Cyrus
Non-Executive Director
3,086 -2.6%
8.32
US$25,676 		3,086 -2.6% 8.32 US$25,676
2025-09-18 2025-09-18 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.3%
8.33
US$83,300 		10,000 -1.3% 8.33 US$83,300
2025-09-18 2025-09-16 S Sale
2.9
Harmon Cyrus
Non-Executive Director
1,914 -1.6%
8.08
US$15,465 		1,914 -1.6% 8.08 US$15,465
2025-09-18 2025-09-16 S Sale
2.9
Harmon Cyrus
Non-Executive Director
10,000 -1.3%
8.04
US$80,400 		10,000 -1.3% 8.04 US$80,400
2025-09-16 2025-09-16 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
11,914
8.04
US$95,827 		11,914 8.04 US$95,827
2025-01-13 2025-01-08 B Purchase
2.9
Bain Capital Life Sciences Investors, LLC
Large shareholder
300,000 +4.0%
5.76
US$1,727,370 		300,000 +4.0% 5.76 US$1,727,370
2024-12-17 2024-12-17 S Sale
3.0
Graham G. Walmsley
Non-Executive Director
700,761 -100.0%
6.75
US$4,730,137 		700,761 -100.0% 6.75 US$4,730,137
2024-12-13 2024-12-13 PrS Proposed sale
Logos Opportunities Fund I LP

Affiliate
700,761
6.75
US$4,730,137 		700,761 6.75 US$4,730,137
2024-12-11 2024-12-11 PrS Proposed sale
2.9
Harmon Cyrus

Director

Non-Executive Director
8,137
8.68
US$70,635 		8,137 8.68 US$70,635
2024-12-11 2024-12-11 PrS Proposed sale
4.1
Kovacs Shane William Charles

Officer

Officer
18,356
8.68
US$159,345 		18,356 8.68 US$159,345
2024-12-11 2024-12-11 PrS Proposed sale
4.1
Myles David C.

Officer

Officer
13,614
8.68
US$118,180 		13,614 8.68 US$118,180
2024-12-11 2024-12-11 PrS Proposed sale
4.0
Zojwalla Naseem

Officer

Officer
14,522
8.68
US$126,062 		14,522 8.68 US$126,062
2024-12-11 2024-12-11 PrS Proposed sale
3.8
Bohen Sean

Officer; Director

Executive Director
57,174
8.68
US$496,322 		57,174 8.68 US$496,322
2024-12-11 2024-12-11 S Sale
2.9
Harmon Cyrus
Non-Executive Director
179 -0.0%
9.39
US$1,681 		179 -0.0% 9.39 US$1,681
2024-12-11 2024-12-11 S Sale
2.9
Harmon Cyrus
Non-Executive Director
7,958 -1.0%
8.66
US$68,916 		7,958 -1.0% 8.66 US$68,916
2024-12-11 2024-12-11 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
406 -0.1%
9.39
US$3,812 		406 -0.1% 9.39 US$3,812
2024-12-11 2024-12-11 S Sale
4.1
Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Officer
17,950 -3.2%
8.66
US$155,447 		17,950 -3.2% 8.66 US$155,447
2024-12-11 2024-12-11 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
300 -0.1%
9.39
US$2,817 		300 -0.1% 9.39 US$2,817
2024-12-11 2024-12-11 S Sale
4.1
Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Officer
13,314 -2.2%
8.66
US$115,299 		13,314 -2.2% 8.66 US$115,299
2024-12-11 2024-12-11 S Sale
3.8
Bohen Sean

PRESIDENT AND CEO

Executive Director
1,267 -0.5%
9.39
US$11,897 		1,267 -0.5% 9.39 US$11,897
2024-12-11 2024-12-11 S Sale
3.8
Bohen Sean

PRESIDENT AND CEO

Executive Director
55,907 -18.7%
8.66
US$484,155 		55,907 -18.7% 8.66 US$484,155
Explore more

More insider trading research around Olema Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America